Document is current
Any future updates will be listed below
-
Authors
Wang, Zeneng
Tang, W. H. Wilson
O’Connell, Thomas
Garcia, Erwin
Jeyarajah, Elias J.
Li, Xinmin S.
Jia, Xun
Weeks, Taylor L.
Hazen, Stanley L. https://orcid.org/0000-0001-7124-6639
-
Funding
Funding for this research was provided by:
national institutes of health (R01HL130819, R01HL103866, P01HL147823)
fondation leducq
- License Information
-
More Information
Article History
Received: 30 September 2021
Accepted: 6 January 2022
First Online: 3 February 2022
Declarations
:
: Drs Hazen and Wang report being named as co-inventors on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. Drs Hazen and Wang report having received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab, a fully owned subsidiary of Quest Diagnostics, and Procter and Gamble. Dr. Hazen is a paid consultant for Zehna Therapeutics and Proctor and Gamble, and has received research funds from Zehna Therapeutics, Proctor and Gamble, Pfizer Inc., and Roche Diagnostics. Dr. Garcia is a current employee of Labcorp, and Drs Jeyarajah and O’Connell are former employees of LipoScience. Dr. Tang is a consultant for Sequana Medical A.G., Owkin Inc, Relypsa Inc., preCARDIA Inc, and Cardiol Therapeutics Inc., Genomics plc, and has received honorarium from Springer Nature for authorship/editorship and American Board of Internal Medicine for exam writing committee participation—all unrelated to the subject and contents of this paper. The remaining authors have nothing to disclose.
: All studies were approved by the Chesapeake Institutional Review Board (now Advarra, Columbia, MD).
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable.
